Treatment
Capivasertib clinical trials
We’re tracking 15 recruiting studies that include Capivasertib, each written for real people, not researchers, below.
Recruiting studies
- NCT05593497RecruitingPhase 2
Combination therapy before prostate surgery for high-risk prostate cancer
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
West Los Angeles, CaliforniaAges 18 years+ - NCT06607757RecruitingPhase 2
Capivasertib plus fulvestrant for high-risk lobular breast cancer
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
AugsburgAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Gilbert, ArizonaAges 18 years+ - NCT02523014RecruitingPhase 2
Drug combo for meningioma that keeps growing despite treatment
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
Birmingham, AlabamaAges 18 years+ - NCT07281833RecruitingPhase 3
Testing capivasertib with hormone therapy for advanced breast cancer
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
AnderlechtAges 18 years+ - NCT07426822RecruitingPhase 2
Preventing Rash and Diarrhea with Capivasertib for Breast Cancer
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
New Haven, ConnecticutAges 18 years+ - NCT07343960RecruitingPhase 1
Study of Capivasertib in people with moderate liver impairment
This trial tests how the drug capivasertib is processed by the body and how safe it is in people with moderate liver impairment. It aims to find the right dose for patients whose liver function is reduced but stable.
Rialto, CaliforniaAges 18–80 - NCT07294677RecruitingPhase 1/Phase 2
Study of capivasertib, venetoclax, and low-intensity chemo for ALL/LBL
This trial tests a combination of targeted drugs (capivasertib and venetoclax) with a gentle form of chemotherapy for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or has not responded to previous treatment. The goal is to see if this approach is safe and effective.
Chicago, IllinoisAges 18 years+ - NCT03903835RecruitingPhase 3
Biomarker-guided treatment for metastatic prostate cancer
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
AalstAges 18 years+ - NCT04812366RecruitingPhase 2
Genetic test-guided treatment before prostate surgery
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
Sacramento, CaliforniaAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05720260RecruitingPhase 2
Test immunotherapy plus hormone therapy and an AKT blocker
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
TaipeiAges 20 years+ - NCT02813135RecruitingPhase 1/Phase 2
Targeted cancer treatment chosen by a tumor’s genetic findings
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
CopenhagenAges Up to 18 years - NCT06927648Recruiting
Safety monitoring study for Capivasertib in Korea
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
BusanAges 19 years+
What Capivasertib is being studied for
Conditions with recruiting Capivasertib studies.
Common questions
- Are there clinical trials studying Capivasertib?
- Yes. Clin2 currently lists 15 recruiting studies that include Capivasertib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Capivasertib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Capivasertib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Capivasertib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.